NEW YORK, June 7 (GenomeWeb News) - Power 3 Medical Products said on Friday that its ongoing collaboration with Baylor College of Medicine to find biomarkers tied to the diagnosis of neurodegenerative diseases has finished its first phase.
According to the company, serum proteins from 79 patients, including ones with Alzheimer's disease, Lou Gehrig's disease, and Parkinson's disease, as well as normal individuals, have been analyzed using Power 3's blood test.
"With this test, which involves monitoring the concentration of nine proteins in the blood, we are able to identify unique biomarkers whose profiles appear to distinguish patients with Lou Gehrig's, Alzheimer's, and Parkinson's diseases from each other as well as from normal patients and patients with other motor neuron and neurological disorders," Ira Goldknopf, CSO of Power 3, said in a statement.
The next confirmatory phase of the partnership, involving the testing of serum from another 104 individuals, is expected to yield results shortly, said Power 3.
Power 3 inherited the Baylor collaboration when it acquired proteomics start-up ProteEx late last month. ProteEx, a Power 3 spokesman said, signed the deal with Baylor in July 2003.